Shell Asset Management CO Vaxart, Inc. Transaction History

Shell Asset Management CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.09 - $4.5 $6,073 - $13,077	-2,906 Reduced 11.65%	22,044 $48,000
Q2 2022 Aug 09, 2022	BUY	$2.7 - $5.28 $118 - $232	44 Added 0.18%	24,950 $87,000
Q1 2022 May 04, 2022	SELL	$4.29 - $6.64 $15,812 - $24,475	-3,686 Reduced 12.89%	24,906 $126,000
Q4 2021 Feb 09, 2022	BUY	$5.77 - $7.96 $750 - $1,034	130 Added 0.46%	28,592 $179,000
Q3 2021 Nov 04, 2021	SELL	$6.67 - $9.8 $8,204 - $12,054	-1,230 Reduced 4.14%	28,462 $226,000
Q2 2021 Aug 12, 2021	BUY	$5.06 - $10.78 $8,146 - $17,355	1,610 Added 5.73%	29,692 $222,000
Q1 2021 May 10, 2021	BUY	$5.64 - $23.33 $158,382 - $655,153	28,082 New	28,082 $170,000

110

37.6M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $73.4M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

Stay updated on Shell Asset Management CO with notifications on news.